xCELLigence RTCA eSight from Agilent Technologies

Product Specs
ItemxCELLigence RTCA eSight
CompanyAgilent Technologies
Price Get Pricing Get Quote for this Product
Catalog Number380601600
QuantityEA
ApplicationsImmuno-oncology and Cell therapy, Cell Viability and Proliferation, Apoptosis, Compound Mediated Cytotoxicity, Cell Mediated Cytotoxicity, Oncolytic viruses, Cell adhesion, Immune cell activation, Real-time Detection of Viral Cytopathic Effects
ModeImaging Modes: Bright field (autoexposure); Three Fluorescence (Blue, Green, Red)
Light SourceHigh power LEDs, auto-LED intensity
Objectives10X; 20X
Resolution10X: 0.86 µm/pixel
20X: 0.43 µm/pixel
CameraCMOS Sensor, 5.0M pixels, up to 35fps, 3.45 µm/pixel, Monochromatic
Power100 to 240 VAC 50 / 60 Hz,
Max: 1.25 A @ 100 VAC; 0.5 A @ 240 VAC
Dimensions(WxDxH) 16.9 x 17.5 x 16.2 in. (or 43.1 x 44.5 x 41.4 cm)
Weight60 lbs; 27.2 Kg
Emission Wavelength430 to 462 nm (blue)
503 to 561 nm (green)
612 to 680 nm (red)
Excitation Wavelength370 to 410 nm (blue)
473 to 491 nm (green)
580 to 598 nm (red)
Configurations3 cradles for E-Plate View 96
2 cradles for other vessels

Specifications/Features

Autofocus methods:image based autofocus
Exported Image Format:JPEG, PNG, TIFF, BMP
Exported Movie Format: WMV, AVI, MPEG-4
Compatible Labware: E-Plate VIEW 96, SBS Standard 96- and 6-well plate, 35 mm, 60 mm cell culture dish with compatible adapter, Corning® T25 cell culture flask with compatible adapter

Add to Compare List

Agilent Technologies

5301 Stevens Creek Blvd

Santa Clara, CA 95051

United States

Phone: +1 877-424-4536

Company Profile

Website: Agilent Technologies

(1) Glycation Interferes with the Expression of Sialyltransferases and Leads to Increased Polysialylation in Glioblastoma CellsCellsDecember 2, 2023Paola Schildhauer, Philipp Selke, Martin S. Staege, Anja Harder, Christian Scheller, Christian Strauss, Rüdiger Horstkorte, Maximilian Scheer, Sandra LeiszAnalysis The impedance real-time cell analysis of the U343 cell proliferation was measured with the xCELLigence RTCA eSight (OmniLife Science, Bremen, Germany). For this, 5 × 103 cells were seeded on E-Plates view 96-well (Agilent Technologies

(2) Therapeutic targeting of tumor spheroids in a 3D microphysiological renal cell carcinoma-on-a-chip systemNeoplasiaDecember 1, 2023Chris P. Miller, Megan Fung, Carla A. Jaeger-Ruckstuhl, Yuexin Xu, Edus H. Warren, Shreeram Akilesh, Scott S. Tykodihalf-media changes every other day for a total of 9-10 days prior to sorting. 2D T-cell killing The xCELLigence RTCA eSight (Agilent, Santa Clara, CA) was used to assess the real-time impedance-based killing capacity of ROR1-specific

(3) First‐in‐human clinical trial of allogeneic, platelet‐derived extracellular vesicles as a potential therapeutic for delayed wound healingJournal of Extracellular VesiclesJuly 1, 2023Jancy Johnson, Sam Q. K. Law, Mozhgan Shojaee, Alex S. Hall, Sadman Bhuiyan, Melissa B. L. Lim, Anabel Silva, Karmen J. W. Kong, Melanie Schoppet, Chantelle Blyth, et al.(Agilent Technologies, USA) in a complete growth medium containing 2% v/v serum, then placed in an xCELLigence RTCA eSight instrument (Agilent Technologies, USA) and their growth monitored overnight. Cells were washed, media

(4) SARS-CoV-2 CD8(+) T cell killing assays using replicating viruses and transgenic antigensSTAR protocolsDecember 16, 2022Mateyka LM, Grass V, Pichlmair A, Busch DH, D'Ippolito E.E-Plate VIEW under a sterile hood for 30 min at 20°C–22°C.16.Place the E-Plate VIEW in the Agilent xCELLigence RTCA eSight instrument (xCELLigence eSight) (37°C, 5% CO2) and set up the experiment according to instrument operational

(5) Protocol for assessment of the efficiency of CRISPR/Cas RNP delivery to different types of target cellsPLOS ONENovember 9, 2021Marina A. Tyumentseva, Aleksandr I. Tyumentsev, Vasiliy G. Akimkinintracellular half-life eGFP-tagged CRISPR/Cas RNP intracellular half-life will be assessed using xCELLigence RTCA eSight (Agilent). Target cells will be seeded at the density of 6×103/well in a company-provided electronic

(6) Cardiac Safety of Kinase Inhibitors – Improving Understanding and Prediction of Liabilities in Drug Discovery Using Human Stem Cell-Derived ModelsFrontiers in Cardiovascular MedicineJune 16, 2021Ricarda Ziegler, Fabian Häusermann, Stephan Kirchner, Liudmila Polonchukunderlying mechanism. Implementation of the next generation hybrid biosensor equipment (e.g., Agilent xCELLigence RTCA eSight), which combines the strengths of real-time impedance monitoring with specificity of the live cell imaging,

(7) YAP inhibits autophagy and promotes progression of colorectal cancer via upregulating Bcl-2 expressionCell Death & DiseaseMay 1, 2021Lan Jin, Yunhe Chen, Dan Cheng, Zhikai He, Xinyi Shi, Boyu Du, Xueyan Xi, Yujing Gao, Yang Guoa 16-well E-plate and incubated at 37 °C. Cell proliferation was continuously monitored by Agilent xCELLigence RTCA eSight for 90 h according to the manufacturer’s protocol. Immunohistochemistry The tumor tissues were deparaffinized

(8) Immune (Cell) Derived Exosome Mimetics (IDEM) as a Treatment for Ovarian CancerFrontiers in Cell and Developmental BiologySeptember 17, 2020Simone Pisano, Irene Pierini, Jianhua Gu, Andrea Gazze, Lewis Webb Francis, Deyarina Gonzalez, Robert Steven Conlan, Bruna Corradetticontrols. Free doxorubicin (at the concentration of 10 μg/mL) was used as a positive control. eSight The xCELLigence RTCA eSight machine (Agilent) was used to obtain real-time impedance-based measurements of cell adhesion and proliferation

(9) Focus on analytical equipment, sensors, and instrumentationPhysics TodayFebruary 1, 2020Andreas Mandelisnoninvasive biosensor measurement with live-cell imaging to deliver deep insight into cellular function. The xCELLigence RTCA eSight continuously monitors cells at predeﬁned temporal resolutions for days or weeks, in a well-controlled,

Be the First to Write a Review!